Dataset opportunity
Gentronix — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Gentronix, usable for Diagnostic AI and Computer Vision.
Score
64.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Partnership (group-level)
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging market was valued at $2.34 billion in 2024, projected to grow at a 33.48% CAGR.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- ✨Signal
Specialized in predictive toxicology and GLP-compliant genetic testing
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Mixed ownership — licensing rights to clarify · PII/regulated
Buyer persona
Medical-AI & diagnostic-imaging companies
Gentronix holds a substantial Medical Imaging Dataset derived from its Contract Research Organization (CRO) activities, supported by extensive medical records and regulatory evidence. This composition makes the data exceptionally well-suited for training and validating Diagnostic AI algorithms, as it includes not only raw images but also crucial contextual information and significant historical control data (HCD), which is essential for building robust and approvable models.
The global AI in Medical Imaging market represents a significant opportunity, valued at $2.34 billion in 2024 and projected to expand at a remarkable 33.48% CAGR. [4] While access is subject to negotiation due to CRO service agreements, client confidentiality, and centralized decision-making under Scantox Group, the rarity and quality of this data in such a rapidly growing market make it a highly valuable strategic asset for any serious AI developer. ⚠ Diligence (valuable data, access to negotiate): Data ownership is governed by CRO service agreements; client confidentiality is paramount.; Significant historical control data (HCD) exists but may require anonymization.; Acquired by Scantox Group in 2023; decision-making likely centralized at group level. · corporate: subsidiary of Scantox Group.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Gentronix owns a massive, proprietary repository of multi-modal toxicology data, including foundational microscopic images from genetic assays. This dataset is a rare asset for medical AI companies developing diagnostic AI to predict genotoxicity and accelerate drug safety screening. In a market growing at over 33% annually, this unique, high-rarity data offers a significant competitive edge by enabling the creation of highly accurate and validated predictive models.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is exceptionally high, driven by the global market for AI in Medical Imaging which is forecast to grow at a 33.48% CAGR. [4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, subsidiary of Scantox Group
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License36
ownership=mixed, licensing=rights_unclear
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence50
subsidiary of Scantox Group
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit83
✓ good target — Good target: Gentronix is a Contract Research Organisation (CRO) whose core business is providing toxicology testing services, which generates valuable genetic and molecular data as a by-product. Issues: Gentronix was acquired by Scantox Group in September 2024 and as of March 2026, now operates under the Scantox brand as 'Scantox Manchester'. [1]; The initial opportunity was listed as 'Medical Imaging Dataset', but the company actually specializes in genetic toxicology, not medical imaging. The data gener
- Deep Qualification90
⚠ needs review — Gentronix, a Contract Research Organization (CRO) specializing in genetic toxicology, primarily generates preclinical data owned by its clients, making the hypothesized 'Medical Imaging Dataset' both mislabeled and unlikely to be available for acquisition. [data is owned by the company's customers; licensing restricted; entity does not hold the niche's characteristic data: The company generates preclinical toxicology data from in-vitro or animal models, not clinical data from human patients like 'diagnostic imaging logs' or 'patient outcome data' as defined by the niche. [2, 7, 12]; dataset_type implausible vs real activity: The target's core business is genetic toxicology, not general medical imaging. Any imaging data would be preclinical and microscopic (e.g., digital pathology), not the clinical diagnostic imaging (X-ray, MRI) implied by the label. [2, 8, 15]]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
The holder possesses an extensive historical database of microscopic images from core genetic toxicology assays, which is invaluable for training computer vision models to automatically detect signs of cellular damage.
Industrial data
This includes proprietary time-series data from high-throughput screening assays, offering a unique, dynamic view into genotoxic mechanisms that is critical for building advanced predictive safety models.
Regulatory records
The dataset is underpinned by decades of GLP-compliant study data, providing the regulatory-grade text and results essential for benchmarking and validating AI models for drug discovery and chemical safety applications.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Gentronix Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $2.34 billion in 2024, projected to grow at a 33.48% CAGR (source: SNS Insider). [4]. Investment score 64.6/100 (confidence 0.49). Recommended action: Partnership (group-level).
From the marketplace
Explore live data opportunities
Microsure — Sensor Telemetry Dataset Opportunity
View opportunity →healthcareDocobo — Medical Imaging Dataset Opportunity
View opportunity →healthcareFilab — Industrial Operations Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Acquire Rare, Compliant Data3 min read
- Data marketplaces, explained4 min read
- Data licensing, term by term4 min read